Tertomotide has anti-tumor related immune activation effects, but it is only used as a research material and cannot be directly used as an anti-cancer drug. Tertomotide is a peptide vaccine that mainly targets telomerase, which can stimulate human immune cells to recognize tumor cells with telomerase. It does not directly kill cancer cells, but awakens its own T cells, allowing immune cells to actively track and eliminate tumor cells. In relevant experiments, Tertomotide can induce specific immune responses, help inhibit tumor growth, and delay lesion progression.
Faithful Chemical offers the products mentioned above. We are committed to providing high-quality service and ensuring that our products are of excellent quality and compliant with international pharmaceutical standards. You can source products from Faithful Chemical with complete confidence.
Tertomotide Description
Tertomotide, also commonly known as GV1001, is an artificially synthesized peptide segment that belongs to the telomerase derived peptide vaccine raw material. It is only used for laboratory research and cannot be directly used to treat human diseases. It is derived from the protein sequence of telomerase reverse transcriptase, and its core function is to stimulate the immune system. Telomerase is highly expressed in many tumor cells, and Tertomotide can guide immune T cells to recognize cancer cells carrying telomerase and trigger specific immune responses. The common form on the market is powder, which has good water solubility and is convenient for preparing mother liquor for cell and animal experiments. It does not have the ability to directly kill tumor cells, and mainly relies on mobilizing its own immune system to exert its effect. It is important to distinguish that Tertomotide is a research peptide raw material, not a marketed drug, and its related immune related effects are still being explored. It is strictly prohibited to use it for human use without authorization. When storing, it is necessary to store at low temperature and avoid light, and try to avoid repeated freezing and thawing to prevent peptide degradation and failure.
Tertomotide is a short peptide synthesized artificially, with a fixed amino acid sequence and a simple and stable structure, which is its core characteristic. Compared with many large molecular proteins, it has a smaller molecular weight, is easier to contact immune cells, and is not easily broken down quickly, making it suitable for conducting experiments related to immune direction. Tertomotide originates from a specific fragment of telomerase reverse transcriptase, which has its own immune recognition site. This structural feature allows it to be captured by antigen-presenting cells, thereby activating specific T cells without indiscriminately stimulating systemic immunity, making it more targeted. The structure of the peptide segment has been optimized with moderate immunogenicity, making it less prone to excessively strong immune storms and convenient for observing slow and sustained immune response changes. At the same time, it also has its shortcomings. Peptides themselves are relatively easy to degrade, and repeated freeze-thaw cycles and prolonged storage at room temperature can damage their structure, leading to a decrease in activity. Therefore, there are strict requirements for storage conditions.
Global Market Description
In cross-border B2B procurement scenarios, experienced buyers in the fields of biotechnology and research and development are no longer solely concerned with whether Tertomotide can induce specific anti-tumor immune responses. They place greater emphasis on impurity control standards, and batch stability of their products to ensure stable and reproducible experimental data in immunotherapy preclinical research and peptide vaccine formulation trials. When formula development personnel purchase Tertomotide for immune pathway research, T cell activation assessment, tumor immune response regulation, and immunological target validation, they should not only consider its basic biological activity, but also focus on core quality indicators to ensure experimental stability and research credibility in cell culture experiments, animal tumor models, and preclinical compound screening systems. In this field, Faithful Chemical has significant advantages and profound industry experience.
| Category | Details |
| Market trend up to 2026 | The global Tertomotide research peptide market maintains steady expansion |
| Advantage of this form | Most versatile and reliable research-grade peptide format |
| Available product form | Research-grade powder |
| Applicable scenarios | In vitro immune function assays, in vivo tumor model administration, preclinical immunotherapy evaluation, laboratory vaccine formulation optimization |
Three Core Driving Forces
01
Growing Demand For Tumor Immunology Research
02
Rising Interest In Anti-Cancer Peptide Vaccine Preclinical Studies
03
Wider Adoption Of This Peptide For Immune Therapeutic Exploration
We utilize advanced equipment and production processes to ensure the high quality of our Tertomotide, meeting international pharmaceutical standards.
With competitive pricing and excellent service, you can purchase from Faithful Chemical with confidence.
Purchasing Notes For Tertomotide
Tertomotide is only for laboratory research use, it is not an approved therapeutic drug and cannot be used for human clinical treatment.
Store Tertomotide at low temperature, avoid repeated freezing and thawing, and keep away from light to prevent peptide degradation and activity loss.
Check the batch test report before purchase to confirm peptide purity, impurity content and batch consistency for repeatable immune tests.
Wear proper protective gear during laboratory operation, and follow biosafety rules for immune-related experiment handling.
Mechanism and Use of Tertomotide
Mechanism of Tertomotide
01
Tertomotide is a peptide fragment derived from telomerase reverse transcriptase. It works as an antigen to be captured and processed by antigen-presenting cells in the immune system.
02
After processing, the peptide is presented on the cell surface, which triggers the activation and proliferation of specific cytotoxic T cells. These T cells can recognize tumor cells that express telomerase.
03
Activated T cells launch targeted immune attacks on tumor cells, restraining tumor growth by starting the body's specific anti-tumor immune response, instead of directly killing cancer cells.
Use of Tertomotide
It is applied for immune response research in tumor immunology labs, to observe T cell activation and antigen recognition processes.
It can be used in animal tumor models to explore anti-tumor immune effects of peptide vaccine candidates.
It supports peptide vaccine formulation development and related immunological target verification work.
Questions Buyers Ask Before Placing A Bulk Order
Conclusion and References
Conclusion
Tertomotide is a synthetic peptide derived from telomerase sequences and is a popular research peptide material in the field of tumor immunology. It does not directly act on tumor cells, but acts as an antigen to awaken specific immunity in the body, helping researchers explore the immune activation mechanisms related to peptide vaccines. The experimental effect of Tertomotide is easily affected by quality and storage methods. When purchasing, priority should be given to products with stable batches and complete quality control. The storage process should avoid light exposure and repeated freeze-thaw cycles to better preserve the biological activity of peptides and ensure the reproducibility of experimental data.
Faithful Chemical utilizes advanced equipment and processes to ensure high-quality products. Our SLU-PP-332 Peptide meets international pharmaceutical standards. Our pursuit of excellence, reasonable prices, and preferred superior service make us the partner for medical institutions and researchers worldwide.
If you require SLU-PP-332 research or production
Please contact Faithful Chemical Click
Email: allen@faithfulbio.com
WhatsApp: +86 13137770562.
References
- Brunsvig PF, et al. Telomerase peptide vaccination: Tertomotide (GV1001) in cancer immunotherapy. Cancer Immunology, Immunotherapy, 2006.
- Bernhardt SL, et al. Immune responses induced by the telomerase peptide GV1001 (Tertomotide) in patients with solid tumors. Vaccine, 2011.
- Aamdal S, et al. Clinical evaluation of Tertomotide peptide vaccine for advanced non-small cell lung cancer. Journal of Clinical Oncology, 2008.
- Inderberg EM, et al. Characterization of T cell responses elicited by Tertomotide, a hTERT-derived peptide antigen. Scandinavian Journal of Immunology, 2012.
- Gjertsen MK, et al. Telomerase-based peptide vaccines and the development of Tertomotide. Expert Review of Vaccines, 2007.
- Solbakk AK, et al. Preclinical assessment of Tertomotide combined with immune adjuvants for enhanced anti-tumor immunity. Journal of Immunology Research, 2015.
- Lislerud K, et al. Stability and formulation considerations for Tertomotide peptide vaccine research. Peptides, 2010.